<DOC>
	<DOCNO>NCT01656551</DOCNO>
	<brief_summary>The purpose study test whether addition cisplatin single agent chemotherapy ( either gemcitabine pemetrexed ) prolongs survival elderly patient non squamous non small cell lung cancer ( NSCLC ) , test whether pemetrexed prolongs survival compare gemcitabine elderly patient non squamous NSCLC .</brief_summary>
	<brief_title>MILES-4 : Study Comparing Gemcitabine Pemetrexed , With Without Cisplatin , Patients With Nonsquamous Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Diagnosis cytologically histologically confirm nonsmall cell lung cancer . Non squamous tumor type ( include nonspecified tumor type ) . Metastatic ( stage IV , M1A M1B ) locally advanced ( stage IIIB , metastasis supraclavicular node ) accord TNM VII edition . Both patient first diagnosis disease recurrence former surgery eligible . At least one target nontarget lesion accord RECIST revise version 1.1 . Male female &gt; = 70 year age . ECOG PS 0 1 . Life expectancy &gt; 3 month . Neutrophils &gt; = 1500 mm3 , platelet &gt; = 100000 mm3 , haemoglobin &gt; = 9 g/dL . Bilirubin level either normal &lt; 1.5 x ULN . AST ( SGOT ) ALT ( SGPT ) &lt; = 2.5 x ULN ( &lt; = 5 x ULN liver metastasis present ) . Serum creatinine &lt; 1.5 x ULN . Signed write informed consent . Prior chemotherapy therapy systemic antineoplastic therapy advance disease . Prior surgery and/or localise irradiation permit . Prior adjuvant chemotherapy permit contain gemcitabine pemetrexed least 6 month elapse end adjuvant chemotherapy . Any unstable systemic disease ( include active infection , significant cardiovascular disease myocardial infarction within previous year , significant hepatic , renal metabolic disease ) , metabolic dysfunction , physical examination finding , clinical laboratory find contraindicates use study medication render patient high risk treatment complication . Any malignancy within 5 year ( except adequately treat carcinoma situ cervix basal squamous cell skin cancer surgically resect prostate cancer normal PSA ) . Patients symptomatic brain metastasis spinal cord compression yet treat surgery and/or radiation ; patient CNS metastases spinal cord compression previously treat surgery and/or radiation eligible asymptomatic require steroid ( antiseizure medication allow ) . Known suspected hypersensitivity study drug</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>elderly</keyword>
	<keyword>chemotherapy</keyword>
</DOC>